Emerging Trends in mRNA Vaccine Technology: Beyond Infectious Diseases
Khormi, A., Qohal, R., Masrai, A., Hakami, K., Ogdy, J., Almarshad, A., Merai, A., harrisi, H., Alotaibi, M., Alotaibi, A., Ghazi, A., Hejry, A., akish, H., GHARAWY, H., FAGEH, M. (2024). Emerging Trends in mRNA Vaccine Technology: Beyond Infectious Diseases. EKB Journal Management System, 67(13), 1567-1574. doi: 10.21608/ejchem.2024.337883.10838
Ali Hassan Ibrahim Khormi; Raied Mohammad Mosa Qohal; Abdulrahman Yahya Ahmed Masrai; Khaloufa Hassan Hofdallh Hakami; Jaber Ahmed Ogdy; Abdu Ahmed Almarshad; Abdullah Mohammed Ahmed Merai; hassan suliman harrisi; Majed Mohammad Alotaibi; Abdulmajeed Mohammad Alotaibi; Ahmed Ibrahim Ahmed Ghazi; Abdullah Ali Abdu Hejry; Hassan Mohammed Ismail akish; HASEN ALI HASEN GHARAWY; MOTTAEN DARWEESH HASAN FAGEH. "Emerging Trends in mRNA Vaccine Technology: Beyond Infectious Diseases". EKB Journal Management System, 67, 13, 2024, 1567-1574. doi: 10.21608/ejchem.2024.337883.10838
Khormi, A., Qohal, R., Masrai, A., Hakami, K., Ogdy, J., Almarshad, A., Merai, A., harrisi, H., Alotaibi, M., Alotaibi, A., Ghazi, A., Hejry, A., akish, H., GHARAWY, H., FAGEH, M. (2024). 'Emerging Trends in mRNA Vaccine Technology: Beyond Infectious Diseases', EKB Journal Management System, 67(13), pp. 1567-1574. doi: 10.21608/ejchem.2024.337883.10838
Khormi, A., Qohal, R., Masrai, A., Hakami, K., Ogdy, J., Almarshad, A., Merai, A., harrisi, H., Alotaibi, M., Alotaibi, A., Ghazi, A., Hejry, A., akish, H., GHARAWY, H., FAGEH, M. Emerging Trends in mRNA Vaccine Technology: Beyond Infectious Diseases. EKB Journal Management System, 2024; 67(13): 1567-1574. doi: 10.21608/ejchem.2024.337883.10838

Emerging Trends in mRNA Vaccine Technology: Beyond Infectious Diseases

Egyptian Journal of Chemistry
Volume 67, Issue 13, December 2024, Page 1567-1574  XML PDF (653.04 K)
Document Type: Review Articles
DOI: 10.21608/ejchem.2024.337883.10838
View on SCiNiTO View on SCiNiTO
Authors
Ali Hassan Ibrahim Khormi email 1; Raied Mohammad Mosa Qohal2; Abdulrahman Yahya Ahmed Masrai3; Khaloufa Hassan Hofdallh Hakami3; Jaber Ahmed Ogdy4; Abdu Ahmed Almarshad5; Abdullah Mohammed Ahmed Merai5; hassan suliman harrisi6; Majed Mohammad Alotaibi7; Abdulmajeed Mohammad Alotaibi8; Ahmed Ibrahim Ahmed Ghazi9; Abdullah Ali Abdu Hejry9; Hassan Mohammed Ismail akish10; HASEN ALI HASEN GHARAWY11; MOTTAEN DARWEESH HASAN FAGEH11
1‏ ksa, Ministry of Health, ‏King Fahad Hospital in jazan ‏
2ksa, Ministry of Health, PMNH in Jazan
3ksa, Ministry of Health, GAZAN HEALTH CLUSTER
4ksa, Ministry of Health, Jazan Health Cluster
5ksa, Ministry of Health, Prince Mohammed Bin Nasser Hospital
6ksa, Ministry of Health, al-edabi general hospital
7ksa, Ministry of Health
8ksa, Ministry of Health, Nafi general hospital
9ksa, Ministry of Health, Prince Mohammed Bin Nasser Hospital
10ksa, Ministry of Health, Al-Baidh Primary Health Care Center
11ksa, Ministry of Health, Jazan Health Cluster
Abstract
Background:

mRNA vaccine technology represents a groundbreaking advancement in biomedicine, achieving global prominence for its pivotal role in mitigating the COVID-19 pandemic. While its success in infectious disease prevention is widely recognized, emerging evidence highlights its vast potential in addressing non-infectious diseases, including cancer, autoimmune disorders, and rare genetic conditions. These developments underscore the transformative capacity of mRNA vaccines to revolutionize therapeutic paradigms and fill critical gaps in medical treatment.

Aim:

This paper aims to explore the expanding frontiers of mRNA vaccine technology, focusing on its applications beyond infectious diseases. Specifically, it evaluates the underlying mechanisms, recent technological advancements, and emerging therapeutic domains, while also addressing existing challenges and identifying priorities for future research.

Methods:

This review synthesizes data from recent preclinical and clinical studies conducted between 2020 and 2024. It examines advancements in mRNA design, delivery systems, and production scalability, alongside the application of mRNA platforms in oncology, autoimmune diseases, and genetic disorders. Sources include peer-reviewed journals, clinical trial reports, and expert reviews, ensuring a comprehensive and critical analysis of the current landscape.

Results:

Advances in mRNA technology, including lipid nanoparticle delivery systems and nucleoside modifications, have significantly enhanced vaccine efficacy and stability. Preclinical and clinical studies demonstrate promising outcomes in the development of personalized cancer vaccines, immune tolerance induction for autoimmune disorders, and protein replacement therapies for rare genetic conditions. Despite these achievements, challenges persist in areas such as cost-effective manufacturing, immunogenicity control, and regulatory standardization.

Conclusion:

mRNA vaccine technology has emerged as a versatile and dynamic platform, poised to address unmet medical needs in diverse therapeutic areas. Its adaptability and precision offer unparalleled opportunities for personalized medicine and disease prevention. However, realizing its full potential requires overcoming current limitations through interdisciplinary research and innovation. Collaborative efforts involving academia, industry, and regulatory bodies are essential to accelerate clinical translation and broaden access to these cutting-edge therapies.
Keywords
Cancer immunotherapy; genetic disorders; lipid nanoparticles; nucleoside modifications; targeted therapy; personalized medicine; biotechnology advancements
Statistics
Article View: 430
PDF Download: 352